Rhythm Pharmaceuticals Inc (STU:1RV)
€ 39.255 -0.74 (-1.85%) Market Cap: 2.43 Bil Enterprise Value: 2.24 Bil PE Ratio: 0 PB Ratio: 42.35 GF Score: 52/100

Rhythm Pharmaceuticals Inc at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 03:05PM GMT
Release Date Price: €18.71 (-0.16%)
David Neil Lebowitz
Morgan Stanley, Research Division - VP

I'm one of the biotechnology analysts at Morgan Stanley, David Lebowitz. And I have with me on the stage from Rhythm Pharmaceuticals, CEO, Keith Gottesdiener. I'm sorry.

Keith Michael Gottesdiener
Rhythm Pharmaceuticals, Inc. - President, CEO & Director

No problem, no one ever uses my last name for exactly that reason.

David Neil Lebowitz
Morgan Stanley, Research Division - VP

I'll call you Keith G. Rhythm is a company that develops therapies for ultra-rare forms of genetic obesity. If you could, I guess, give us a top level just on the company and bring us up to speed on the recent updates.

Keith Michael Gottesdiener
Rhythm Pharmaceuticals, Inc. - President, CEO & Director

Sure. So Rhythm is a company, as David said, that focuses on rare genetic causes of obesity, and we are focused on the pathway in the brain called the melanocortin-4, MC4 pathway, which is probably the key pathway in the brain that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot